Corvus Pharmaceuticals Inc (CRVS)
2.29
+0.10
(+4.57%)
USD |
NASDAQ |
May 17, 16:00
2.29
0.00 (0.00%)
After-Hours: 20:00
Corvus Pharmaceuticals Enterprise Value: 121.11M for May 17, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 17, 2024 | 121.11M |
| May 16, 2024 | 114.86M |
| May 15, 2024 | 116.74M |
| May 14, 2024 | 119.24M |
| May 13, 2024 | 109.86M |
| May 10, 2024 | 107.98M |
| May 09, 2024 | 104.85M |
| May 08, 2024 | 100.47M |
| May 07, 2024 | 82.96M |
| May 06, 2024 | 97.34M |
| May 03, 2024 | 72.03M |
| May 02, 2024 | 62.71M |
| May 01, 2024 | 56.82M |
| April 30, 2024 | 53.88M |
| April 29, 2024 | 55.35M |
| April 26, 2024 | 48.98M |
| April 25, 2024 | 50.45M |
| April 24, 2024 | 51.92M |
| April 23, 2024 | 52.90M |
| April 22, 2024 | 48.49M |
| April 19, 2024 | 46.53M |
| April 18, 2024 | 47.02M |
| April 17, 2024 | 44.56M |
| April 16, 2024 | 49.96M |
| April 15, 2024 | 49.96M |
| Date | Value |
|---|---|
| April 12, 2024 | 52.90M |
| April 11, 2024 | 54.37M |
| April 10, 2024 | 51.92M |
| April 09, 2024 | 57.80M |
| April 08, 2024 | 61.73M |
| April 05, 2024 | 63.69M |
| April 04, 2024 | 60.75M |
| April 03, 2024 | 63.69M |
| April 02, 2024 | 69.08M |
| April 01, 2024 | 69.08M |
| March 28, 2024 | 60.14M |
| March 27, 2024 | 60.63M |
| March 26, 2024 | 59.16M |
| March 25, 2024 | 59.16M |
| March 22, 2024 | 60.63M |
| March 21, 2024 | 63.08M |
| March 20, 2024 | 63.57M |
| March 19, 2024 | 68.97M |
| March 18, 2024 | 66.02M |
| March 15, 2024 | 66.02M |
| March 14, 2024 | 65.04M |
| March 13, 2024 | 70.93M |
| March 12, 2024 | 71.91M |
| March 11, 2024 | 71.42M |
| March 08, 2024 | 76.81M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-26.95M
Minimum
Mar 16 2020
295.39M
Maximum
Sep 21 2021
37.35M
Average
34.36M
Median
Jan 06 2022
Enterprise Value Benchmarks
| Cyclacel Pharmaceuticals Inc | -0.3591M |
| Enanta Pharmaceuticals Inc | -43.40M |
| Oragenics Inc | 8.862M |
| Nanoviricides Inc | 21.13M |
| MAIA Biotechnology Inc | 64.01M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -5.701M |
| Total Expenses (Quarterly) | 6.253M |
| EPS Diluted (Quarterly) | -0.12 |
| Earnings Yield | -22.27% |